Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 9Cerebrolysin literaturebiorxiv-preprint · Meta-analysis2026

Post-EVT CTP Imaging as a Patient-Selection Tool for Adjuvant Therapy: Review, Meta-Analysis, and Clinical Threshold Framework

Post-EVT CTP imaging may help predict functional outcomes in stroke patients, with specific thresholds potentially guiding adjuvant therapy selection.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the cerebrolysin corpus
1
Preclinical
6
Observational
0
Open-label
0
Randomised
2
Reviews · this one

Summary and findings

This meta-analysis evaluated the role of post-endovascular thrombectomy (EVT) CT perfusion (CTP) imaging in predicting functional outcomes in stroke patients. It synthesized data from nine studies involving 497 patients, focusing on the association between residual hypoperfusion and functional independence. The findings suggest that specific CTP thresholds could aid in patient selection for adjuvant therapies.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Pooled OR for functional independence with post-EVT hypoperfusion versus without was 0.23, 95% CI 0.17–0.33; I²=29%.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>Background and Purpose</h4> Despite high rates of macrovascular recanalization, approximately half of patients with large vessel occlusion stroke fail to achieve functional independence after endovascular thrombectomy (EVT). Residual tissue-level perfusion abnormalities on post-procedural CT perfusion (CTP) may indicate futile recanalization and inform selection for adjuvant therapy. We synthesized post-EVT CTP thresholds, summarized acquisition timing, and discussed implications for patient selection in trials of intra-arterial thrombolysis, antithrombotics, and neuroprotection, limited to studies performing perfusion imaging after EVT. <h4>Methods</h4> We searched MEDLINE, EMBASE, and the Cochrane Library (January 2018–April 2026) for studies performing perfusion imaging after EVT, reporting ≥1 quantitative CTP parameter with functional or neurological outcome, and enrolling ≥10 patients; pre-EVT CTP studies were excluded. Functional independence with versus without post-EVT hypoperfusion was pooled using DerSimonian–Laird random-effects. Individual patient data from our prospective Cerebrolysin proof-of-concept cohort (N=18) were integrated. <h4>Results</h4> Nine post-EVT perfusion imaging studies (497 patients) met inclusion criteria. Residual hypoperfusion occurred in 21–53% of angiographically successful reperfusions and was associated with lower odds of functional independence (pooled OR 0.23, 95% CI 0.17–0.33; I²=29%). A Tmax >6 s volume <3.5 mL at 30–90 minutes post-EVT was the most consistently validated threshold (OR 3.5, 95% CI 1.6–7.8). In our cohort, an ischemic core (rCBF <30%) of 0 mL versus any detectable residual core was associated with markedly higher odds of independence (OR 27.5, 95% CI 1.0–746 with continuity correction; ρ=0.77, p=0.003). The optimal CTP acquisition window is 30–120 minutes post-EVT. <h4>Conclusions</h4> Post-EVT CTP outperforms modified TICI grading for predicting functional outcome and identifies biologically distinct subgroups for adjuvant therapy selection. Standardized post-EVT CTP at 30–120 minutes, applied with the proposed threshold framework, should be used for eligibility and stratification in future trials of intra-arterial thrombolysis, antithrombotics, and neuroprotection.

Elsewhere in the Cerebrolysin corpus

BCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2024 · Hazard ratio for symptomatic HT in HTI > 0 cohort: 0.245 (95% CI 0.072–0.837; p = 0.020)HumanAEfficacy of Cerebrolysin Treatment as an Add-On Therapy to Mechanical Thrombectomy in Patients With Acute Ischemic Stroke Due to Large Vessel Occlusion in Anterior Circulation: Results of a three-month follow-up of a Prospective, Open Label, Single-Center Studybiorxiv-preprint · 2025 · 68% mRS 0–2 at 90 days vs 44% in controls, p=0.016, OR 2.7, 95%CI 1.2 - 6.1; NNT: 4.2HumanBA Real-World Data Analysis of Adverse Drug Reactions Associated with Neuroprotective Agents: Insights from WHO-VigiAccessbiorxiv-preprint · 2025 · 132,476 ADR reports for Cerebrolysin.HumanBCerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trialbiorxiv-preprint · 2025 · HR = 0.245; 95 % CI 0.072–0.837; p = 0.020 for symptomatic HT in high-risk patients.HumanAABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKEeuropepmc · 2026HumanBNeuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Month Prospective Cohort Analysis.europepmc · 2025 · CRS-R scores at discharge: 20.3 ± 2.7 vs. 16.4 ± 2.1; p = 0.013.Human